Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 6744 (miR-6744) is a small non-coding RNA molecule that regulates gene expression post-transcriptionally by binding to target mRNAs and reducing their translation or promoting degradation. MiR-6744-5p plays a key tumor suppressive role in breast cancer cell lines by promoting anoikis, a form of apoptosis induced by loss of cell attachment to the extracellular matrix, thereby acting as a barrier to metastasis. Experimental studies show that miR-6744-5p is downregulated in anoikis-resistant breast cancer sublines, and overexpression restores sensitivity to anoikis while decreasing migration and invasiveness. The N-acetyltransferase 1 (NAT1) enzyme was identified as a direct downstream target of miR-6744-5p, linking its regulatory function to key processes in cell survival, EMT, and metastatic progression. Expression levels of miR-6744-5p, as well as its impact on E-cadherin, highlight its importance as a potential therapeutic target and biomarker in breast cancer.
miR-6744-5p functions by downregulating target mRNA, specifically the N-acetyltransferase 1 (NAT1) enzyme, resulting in increased sensitivity to anoikis and decreased migration/invasion in breast cancer cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 6744 (miR-6744).